In this current study, we detected the plasma neutralization ability against EBV infection of epithelial cells and B cells and the levels of IgG and IgA antibodies targeting EBV glycoproteins including gp350, gH/gL, gB, and gp42 in incident NPC cases, high-risk healthy controls (HC), and low-risk healthy controls (LC) from the screening program in Sihui County in Guangdong Province of China. This evidence concerns the gene CD79A and nasopharyngeal carcinoma.